58 results about "Cellular activity" patented technology

The invention provides a method for distinguishing cell activity behaviors in a culture medium under the assistance of a computer, and relates to the technical field of cell image processing, and the method comprises the following steps: obtaining a target microscopic image of a target cell at the current moment, extracting the static characteristics of the target cell in the target microscopic image, and if the recognition confidence is lower than a first threshold value, determining that the target cell is a cell activity behavior; if yes, calling a historical image sequence of an area where the target cell is located; at least N candidate images are obtained through screening in the historical image sequence, time sequence dynamic characteristics of the target cells are obtained based on the candidate images, and the time sequence dynamic characteristics comprise the motion trail, the motion speed, the morphological change related to the activity behavior and the periodic change condition presented by the target cells within a certain time period; and combining the time sequence dynamic characteristics with the static characteristics, and carrying out activity behavior matching to obtain activity behaviors of the target cells. According to the method, the robustness and the accuracy of cell behavior recognition in a complex culture environment are remarkably improved through static-dynamic feature fusion.

The invention relates to an antibody drug conjugate which is shown in a formula (I) and contains two or more bioactive molecules with different action mechanisms, a preparation method of the antibody drug conjugate, and application of the antibody drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #

An antibody-drug conjugate as shown in formula I, a preparation method therefor, and a use thereof in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to a use in prevention and / or treatment of tumor diseases.

Provided herein are compositions comprising a particle comprising a library encoded bead (e.g., DEL bead) coated in a polymeric matrix forming a core-shell particle, wherein the core-shell particle is further inside a 3D tissue culture. Also provided herein are methods of making such particles, and methods of using such particles for drug discovery such as identification of bioactive compounds via high-throughput cellular activity-based phenotypic screens of DNA-encoded chemical library beads.

The invention discloses a differential low-noise integrated biosensor array for cell culture detection and a preparation method thereof, and the differential low-noise integrated biosensor array integrates an ISHFET device, an REHFET device and an EXHFET device, so that extracellular action potential signals and local field potential signals can be detected during in-vitro cell culture; therefore, interference of factors such as tissue trauma and immune response on cell activity signal detection is avoided, and good reliability is realized; the ISHFET device and the REHFET device can form a differential sensing unit, so that the effect of reducing the detection error is realized; the EXHFET device not only can detect extracellular action potential signals, but also can independently detect local field potential signals, so that more diversified cell activity signals can be detected, and more data support is provided for in-vitro cell culture research. The method is widely applied to the technical field of semiconductors.

The invention relates to the technical field of microalgae biology, in particular to a chlamydomonas reinhardtii strain with high yield of exosomes, which is named as Chlamydomonas reinhardtii YYAW026 and preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.46629, the preservation date is November 10, 2025, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. Compared with an original strain, the chlamydomonas reinhardtii cell provided by the invention cannot form a complete cell wall structure, so that the exosome can be quickly secreted into a culture solution; although the cell structure of the strain is incomplete, the strain can still perform normal cell activity, the growth curve is basically consistent with that of a wild type, the yield of the exosome of the strain is greater than that of the wild type when the strain reaches a plateau phase, and the particle size distribution width of the exosome is more concentrated. The chlamydomonas reinhardtii disclosed by the invention has a relatively good application prospect in the basic research fields of cosmetics, medical beauty industry and algae source exosomes.

This disclosure relates to pharmaceutical combinations for treating and / or preventing cancer and methods and uses thereof. More particularly, provided are pharmaceutical combination comprising a PRMT5 Inhibitor and a cellular activity modulator selected from an EGFR inhibitor, a KRAS inhibitor, a KRAS-G12C inhibitor, a MEK inhibitor, a Bcl-2 inhibitor, a SOS1 inhibitor, a PARP inhibitor, a RAF inhibitor, a ERK inhibitor, a CDK4 / 6 inhibitor, a MALT1 inhibitor, a BTK inhibitor, MAT2A inhibitor, a PI3K inhibitor, a AKT inhibitor, a FGFR inhibitor, a Type I PRMT inhibitor, a STING agonist, or an immune checkpoint inhibitor / modulator.

The invention relates to an antibody drug conjugate of a cardiac glycoside and / or cardiac aglycone compound as shown in a formula (I), a preparation method of the antibody drug conjugate and application of the antibody drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #

Disclosed herein is a series of helical sulfono-γ-AApeptides that mimic the binding mode of the α-helical HD2 domain of B-Cell Lymphoma 9 (BCL9). As disclosed herein, sulfono-γ-AApeptides can structurally and functionally mimic the α-helical domain of BCL9, and selectively disrupt β-catenin / BCL9 PPIs with even higher potency. More intriguingly, these sulfono-γ-AApeptides can enter cancer cells, bind with β-catenin and disrupt β-catenin / BCL PPI, and exhibit excellent cellular activity, which is much more potent than the BCL9 peptide. Furthermore, enzymatic stability studies demonstrated the remarkable stability of the helical sulfono-γ-AApeptides, with no degradation in the presence of pronase for 24 h, augmenting their biological potential.

The present disclosure relates to means of treating ocular axis length diseases, such as myopia. The optical films of the present invention include apparatuses and methods for formulating, selecting, supplying and assembling permanent or non-permanent optical films for use with standard monochromatic eyeglasses, where the apparatuses and methods are configured with non-refractive opaque features, wherein the non-refractive opaque feature promotes an increase in the whole retinal ganglion cell activity of the wearer, which can be used as an optical signal to slow, improve, control, inhibit or reduce the speed of myopia progression in the wearer.

The present disclosure relates to means for treating axial length disorders, such as myopia, and includes apparatus and methods for prescribing, selecting, supplying, and fitting permanent or non-permanent optical films for use with standard single-vision eyeglasses, wherein the apparatus and methods are configured with non-refractive opaque features, wherein the non-refractive opaque features promote an increase in retinal ganglion cell activity throughout the wearer's retina, which can be used as an optical signal to slow, improve, control, inhibit, or reduce the rate of myopia progression in the wearer.

This invention provides rice OsPDRA3 Application of genes in improving insect resistance in rice. This invention clones genes from the rice genome. OsPDRA3 Gene (LOC_Os01g42380), analyzed using the SMART program, predicts that this protein possesses multiple transmembrane domains and ATPase domains (AAA+) associated with various cellular activities. Further investigation is needed. OsPDRA3 The effect on tolerance of rice brown planthopper was investigated by comparing wild-type and overexpression. OsPDRA3 The tolerance of transgenic plants to brown planthoppers was assessed, and the results showed that overexpression of [the planthopper species]... OsPDRA3 Compared to wild-type rice lines (0% survival rate), the survival rate of rice lines treated with brown planthoppers was significantly improved, reaching 75%–100%. This indicates that… OsPDRA3 Genes can significantly improve the insect resistance of rice and can be widely used in the fields of plant genetic engineering and plant disease resistance, with huge economic value and application prospects.

The present application relates to a quinazoline derivative of general formula (I) or stereoisomer, pharmaceutically acceptable salt, solvate, or tautomer, which can selectively inhibit CDK9 and / or TNIK, and has good enzymatic and cellular activity.

The invention relates to a bioactive substance conjugate as well as a preparation method and application thereof, and particularly discloses a ligand drug conjugate as shown in a formula XV, a preparation method thereof and application of the ligand drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #

Provided herein are systems and methods for measuring cellular activity within a biological sample comprising living cells over an extended time period. In particular, provided herein are techniques for measuring changes in cellular activity within a tissue sample comprising living cells (e.g., a tissue section comprising living cells) during and / or after exposure to a first stimulus (e.g., a control stimulus) at a first time point and during and / or after exposure to a second stimulus (e.g., a non-control stimulus) (e.g., a pharmaceutical stimulus) at a second time point after the first time point.

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The present invention relates to a non-invasive magneto-acoustic apparatus for healthy tissue healing and cancer regression comprising at least one pulsed ultrasound unit (LIPUS), at least one permanent magnet, at least one module housing, at least one permanent magnets, at least one control system for controlling pulsed ultrasound unit to energize the unit with desired pulse duration, intensity and active / ON time. The invention is to synchronously use the low intensity pulsed ultrasound (LIPUS) and static magnetic field (SMF) to selectively activate cellular activities specific to cartilage, bone, skin leading to accelerated tissue healing, regeneration. The invention apparatus is to inhibit cancer cellular activities specific to cancers of breast, skin, bone leading to enhanced cancer regression, while leaving the healthy cells unaffected using magneto-acoustic apparatus appropriately. The apparatus exhibit no toxicity to healthy cells and can reduce overall treatment time and costs due to accelerated tissue repair and tumor regression.

The invention relates to a bioactive substance conjugate as well as a preparation method and application thereof, and particularly discloses a ligand drug conjugate as shown in a formula XV, a preparation method thereof and application of the ligand drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #

The present invention relates generally to compositions and methods for modulating cell activity using multi-characteristic opsin proteins (MCOs). In addition, the present invention provides methods of treating conditions associated with dorsal root ganglion (DRG), anterior clasps cortex (ACC), or spinal cord activity, including neuropathic pain. Particular embodiments include methods of modulating an inhibitory pathway to inhibit chronic neuropathic pain. The method may use a photosensitive optogenetic actuator with inhibitory neuron specificity. Embodiments also include an optogenetic pain regulator device that can regulate the frequency and intensity of optogenetic stimulation.

The present application provides a computer-assisted method for distinguishing cell activity behaviors in a culture medium, which relates to the field of cell image processing technology and includes the following steps: obtaining a target microscopic image of a target cell at the current moment, and extracting the static features of the target cell in the target microscopic image; if the recognition confidence is lower than a first threshold, retrieving a historical image sequence of the area where the target cell is located; screening at least N candidate images in the historical image sequence, and obtaining temporal dynamic features of the target cell based on the candidate images. The temporal dynamic features include the motion trajectory, motion speed, morphological changes and periodic changes related to the activity behavior of the target cell within a certain time period; combining the temporal dynamic features with the static features to perform activity behavior matching to obtain the activity behavior of the target cell. The present application significantly improves the robustness and accuracy of cell behavior recognition in complex culture environments through the fusion of static and dynamic features.

The present disclosure generally relates to, inter alia, a new class of chimeric Notch receptors containing a fully humanized transcriptional effector, engineered to modulate gene expression and cellular activities in a ligand-dependent manner. The new chimeric Notch receptors surprisingly retain the ability to transduce signals in response to ligand binding despite that the Notch extracellular subunit (NEC), which includes the negative regulatory region (NRR) previously believed to be essential for the functioning of Notch receptors is completely absent. In addition, the new receptors described herein incorporate an extracellular oligomerization domain to promote oligomer formation of the chimeric receptors. Also provided are compositions and methods useful for producing such receptors, nucleic acids encoding same, engineered cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and / or for the treatment of various diseases such as cancers.

Synthetic polymer networks have been introduced into mammalian cells, rendering them incapable of dividing while retaining cellular activity. A variety of mammalian cell types, useful for example in tissue regeneration and reducing inflammation in mammals, have been generated by the inventors and found to produce a number of desirable growth factors, chemokines, cytokines and other factors, indicating uses in therapy for mammals in need of these factors.

This invention provides an N-aryl-N-arylpropynyl-arylacetamide compound and its pharmaceutical uses. The provided compounds include their prodrugs, tautomers, stereoisomers, solvates, isotopic derivatives, or pharmaceutically acceptable salts thereof. The compounds of this invention can serve as the first covalent inhibitor of POLQ. In vitro enzyme activity inhibition studies show that the compounds of this invention have strong inhibitory effects on POLQ enzymes and can serve as promising compounds for the treatment of POLQ-mediated diseases. Further studies have shown that typical compounds I-1, I-13, and I-25 have considerably long-lasting inhibitory activity against POLQ enzymes and good cellular activity. The synthetic method of this invention is simple and convenient, facilitating large-scale industrial production and application. The general structural formula of this invention is shown in Formula I:

The invention relates to a bioactive substance conjugate and a preparation method and application thereof, in particular to a novel bioactive molecule conjugate obtained by improving the coupling mode of a drug in ADC or SMDC and a targeting part, a preparation method of the novel bioactive molecule conjugate and application of the novel bioactive molecule conjugate to preparation of drugs for treating cell activity abnormity related diseases.

The invention provides for compositions comprising phosphorous containing tricyclic compounds, including phthalazin-1(2H)-one derivatives. The compounds are potent inhibitors of the enzyme poly(ADP-ribose)polymerase (PARP), particularly PARP-1 and potentially PARP-2. The also show good cellular activity in inhibiting poly(ADP-ribose) oligomer formation. The compounds may be useful as mono-therapy or in combination with other therapeutic agents in the treatment conditions where PARP is implicated, such as cancer, inflammatory diseases and ischemic conditions. Thus, also provided are methods for the treatment of a condition where PARP is implicated comprising administering to an effective amount of a compound of the invention to an individual in need thereof.

The invention belongs to the field of medical chemistry, and particularly discloses a diacylpyrrole histone deacetylase 6 inhibitor and application thereof, and the diacylpyrrole histone deacetylase 6 inhibitor is a compound shown in a general formula (I) or pharmaceutically acceptable salt of the diacylpyrrole histone deacetylase 6 inhibitor. The invention also discloses a pharmaceutical composition containing the compound. The pharmaceutical composition can be used for preventing or treating clinical diseases related to HDAC1 or HDAC6. Compared with a reported clinical selective HDAC6 inhibitor, the enzyme activity and the cell activity of the HDAC6 inhibitor in the patent are remarkably improved.

To provide a method for treating cancer and autoimmune diseases by in vivo transforming immunosuppressive tumor-associated macrophages (TAMs) that support cancer growth and metastasis into highly activated tumoricidal macrophages.SOLUTION: Provided is a method for altering the activation state of macrophages within a tumor in vivo, comprising administering to a tumor site nanoparticles comprising a poly(β)-amino ester core and a polyglutamic acid coating, in which in vitro transcribed mRNA encoding (i) one or more interferon regulatory factors (IRFs) and (ii) IKKβ are encapsulated within the core, the activation state of the macrophages being altered from an inactivated state to an activated state.SELECTED DRAWING: None

The invention relates to an antibody drug conjugate containing a phenanthroquinolizidine compound as shown in a formula I, a pharmaceutical composition, a preparation method of the antibody drug conjugate, and application of the antibody drug conjugate in prevention and / or treatment of cell activity abnormity related diseases, including but not limited to prevention and / or treatment of tumor diseases. The antibody drug conjugate can realize tumor enrichment, eliminate or reduce toxic and side effects caused by the phenanthroquinolizidine compound acting on non-disease tissues, and improve the treatment effect.

An apparatus for measuring brain cell activity in artificial blood circulation according to an embodiment of the present invention may include a measuring unit (10) that measures EEG signals; an analog-to-digital converter (ADC) 20 that converts the EEG signals measured at the measuring unit 10 into digital signals; a control unit 50 that calculates EEG parameters from the digital EEG signals converted at the ADC 20, and calculates end-tidal carbon dioxide tension and cerebral blood flow from the EEG parameters.

The present application relates to an antibody drug conjugate containing phenanthroquinolizidine compound as shown in formula I, a pharmaceutical composition, a preparation method thereof, and the use thereof in preventing and / or treating diseases related to abnormal cell activity, including but not limited to preventing and / or treating tumor diseases. The antibody drug conjugate can achieve tumor enrichment, eliminate or reduce the toxic side effects caused by the action of phenanthroquinolizidine compound on non-disease tissues, and improve the therapeutic effect.